(UroToday.com) In this abstract, Dr. Gschwend reports the impact of nivolumab vs. placebo on health-related quality of life (HRQoL) outcomes in the CheckMate-274 trial.1 In the phase 3, randomized, double-blind, multicenter CheckMate 274 trial (NCT02632409), patients with high-risk muscle-invasive urothelial carcinoma (MIUC) who had undergone radical resection were randomized 1:1 to adjuvant nivolumab (NIVO) 240 mg Q2W or placebo (PBO) for ≤1 year. NIVO significantly prolonged disease-free survival (DFS) in both all randomized patients and patients with PD-L1 expression ≥1%. The full results were previously reported at ASCO GU 2021.